To benchmark the utility of E06: A half-life extension, single-domain, shark antibody bio-tool, and progress it to a Phase 1 ready candidate clone

点击翻译按钮获取中文摘要

Scientifically we are developing a "bio-tool" that could be fused to a range of different therapeutic proteins/peptides to extend their serum half-life from hours to weeks, with the potential of greatly increasing their therapeutic potency. It works by hitching a ride on other long-lived proteins in the blood. Commercially, our medium-term goal is to create a Drug Discovery company, based on our unique, single-domain shark antibody (VNAR) platform, which will develop therapeutic agents in-house or in partnership with larger companies. To achieve this, meeting of scientific milestones is key, and in particular confirming non-immunogenicity (not seen by the human immune system & safe for use), and validate the most advanced of our products (E06 VNAR half-life extension bio-tool). Progress towards this goal will also provide a platform for NewCo formation and equity raising, and will deliver an asset capable of securing multiple revenue streams of licensing and partnered income.